Link: Yorkshire Post Today
BIOFUSION, the company that commercialises the life sciences work of Sheffield University, has launched a new company Absynth Biologics which is working on a treatment for the deadly MRSA hospital bug.
Absynth will develop vaccines and antibodies to treat infections caused by the bacterium Staphylococcus aureus, including its drug-resistant form MRSA.
Biofusion has agreed to invest up to £325,000 in the company to enable it to produce possible vaccines and antibodies to begin the clinical trial process
